-
3 weeks ago | 
onlinelibrary.wiley.com | Peter Tyrer |Helen Tyrer |Gin S Malhi
1 Introduction It is well established that the course of bipolar disorder may be preceded by other affective symptoms, and these may precede the first episode of hypomania or mania by many years. Apart from genetic predisposition and childhood instability of mood, there are few data examining affective symptoms and personality status in those that develop bipolar disorder.
-
Oct 16, 2024 | 
cambridge.org | Hugo D. Critchley |Derek Tracy |Gin S Malhi |Laith Alexander
Hostname: page-component-788cddb947-kc5xbTotal loading time: 0Render date: 2024-10-16T08:52:23.916ZHas data issue: falsehasContentIssue false Published online by Cambridge University Press: 16 October 2024Hugo D. Critchley [Opens in a new window] ,Derek K. Tracy [Opens in a new window] ,Gin S. Malhi [Opens in a new window] ,Laith Alexander [Opens in a new window] ,David S. Baldwin [Opens in a new window] ,Jonathan Cavanagh [Opens in a new window] ,Samuel R.
-
Oct 4, 2024 | 
cambridge.org | Gin S Malhi |Erica Bell
Britain's historical contributions to the promotion of lithium as a treatment for bipolar disorder have occurred episodically, somewhat like the illness it best treats. At different times over the past century and a half, British research into the effects of lithium and the opinions of leading figures in psychiatry and psychopharmacology on its clinical efficacy have both promoted and hindered its use.
-
Aug 31, 2024 | 
onlinelibrary.wiley.com | Gin S Malhi |Erica Bell |Uyen Le |Philip Boyce
In a case of long-standing, complicated major depression, esketamine was added to typical therapeutic agents used to overcome non-response. This case exemplifies how even in severe depression that has failed to respond to extensive treatment with diverse interventions, substantive improvements remain possible. Thus, depression described as ‘treatment resistant’ should not necessarily be regarded as irremediable.
-
Aug 29, 2024 | 
onlinelibrary.wiley.com | Gin S Malhi |Erica Bell
Corresponding Author Gin S.
-
Aug 22, 2024 | 
cambridge.org | Gin S Malhi
The Feature articleReference Bastidas-Bilbao, Castle, Gupta, Stergiopoulos and Hawke1 in this issue of the BJPsych is the product of a somewhat unique situation in Canada, where, although legislation has been passed to provide medical assistance in dying (MAiD) to those with a mental illness, its implementation has been deferred because of widespread concerns regarding its provision to so-called vulnerable populations.
-
May 23, 2024 | 
onlinelibrary.wiley.com | Gin S Malhi |Uyen Le |Erica Bell |Cornelia Kaufmann
Adding esketamine to lamotrigine was explored with promising results in a clinical trial. Lamotrigine, a bipolar disorder mood stabiliser, occasionally used to treat major depression, shares mechanisms of action with esketamine suggesting combinatorial benefits. Whether this effect is synergistic, augmenting or neither is discussed to advance clinically meaningful examination.
-
Mar 25, 2024 | 
cambridge.org | Gin S Malhi |Erica Bell
We read with interest Dr Connors reply (Connors, Reference Connors2023a) to our letter to the editor (Malhi et al., Reference Malhi, Jadidi and Bell2023b) in which we had questioned a number of aspects of his thoughtful examination of paediatric bipolar disorder (PBD) (Connors, Reference Connors2023b). We were reassured by his response because, with respect to the points that Dr Connors feels we critiqued, we believe that our views are in fact largely aligned.
-
Sep 20, 2023 | 
psiquiatria.com | Gin S Malhi
Autor/autores:
Gin S. Malhi, Maedeh Jadidi y Erica Bell
Un reciente reexamen del trastorno bipolar pediátrico (PBD), realizado por Peter Parry y sus colegas en esta revista (Parry et al. 2021 ), revela una vez más que el diagnóstico de una enfermedad bipolar sigue siendo un desafío, especialmente en los jóvenes, donde la Algunos utilizan el término PBD para describir la aparición de síntomas bipolares en personas menores de 18 años.
-
Sep 19, 2023 | 
psiquiatria.com | Gin S Malhi |Erica Bell
Desde hace más de medio siglo se sabe ampliamente que el litio es el tratamiento más eficaz para el trastorno bipolar. Sin embargo, a pesar de esto, su prescripción ha disminuido constantemente durante este mismo período de tiempo.
Se han propuesto varias razones para esta aparente disparidad entre la evidencia y la práctica clínica, incluida la falta de confianza entre los médicos, posiblemente debido a la falta de capacitación y falta de familiaridad con la molécula.
